ABSTRACT
OBJECTIVES: The aim of this study was to investigate the relationship between thromboxane levels and oxidative stress in children with Crohn´s disease (CD), and examine the effect of natural polyphenolic compounds on thromboxane levels. METHODS: This study involved 14 children suffering from CD and 15 healthy controls. Patients were receiving the polyphenolic extract Pycnogenol for 10 weeks. Plasma levels of the static and dynamic forms of thromboxane B2 as well as their metabolite 11-dehydro thromboxane B2 in urine were determined. RESULTS: In comparison to controls, CD patients had significantly higher levels of the static and dynamic forms of thromboxane B2. Pycnogenol decreased the level of the dynamic form of thromboxane B2 after 10 weeks of administration. CONCLUSIONS: Paediatric Crohn's disease is associated with higher thromboxane levels. Our results indicate that Pycnogenol administration reduces thromboxane levels, which may positively influence some clinical symptoms of CD such as thromboembolic episodes (Tab. 3, Ref. 49).
Subject(s)
Crohn Disease/metabolism , Oxidative Stress/drug effects , Polyphenols/pharmacology , Thromboxanes/blood , Adolescent , Antioxidants/metabolism , Biomarkers/metabolism , Case-Control Studies , Crohn Disease/blood , Crohn Disease/diagnosis , Crohn Disease/drug therapy , Female , Flavonoids/administration & dosage , Humans , Male , Plant Extracts/administration & dosage , Polyphenols/administration & dosageABSTRACT
Crohn's disease (CD) is a nonspecific, chronic inflammatory disease of the gastrointestinal tract. It is supposed that in etiopathogenesis oxidative stress (OS) plays a role. However, its precise role in the active and non-active states of disease is not known yet. We conducted a pilot study focusing on the relationship between OS of CD in remission and the possibility to influence clinical parameters and markers of OS by polyphenolic extract, Pycnogenol® (Pyc). Compared to 15 healthy controls 15 pediatric CD patients (all were in remission according to their disease activity index - PCDAI) had reduced the activity of Cu/Zn-superoxide dismutase (SOD) and increased the oxidative damage to proteins. We found negative correlations between markers of inflammation (calprotectin, CRP) as well as between PCDAI and total antioxidant capacity (TAC). Activities of antioxidant enzymes, SOD, and glutathione peroxidase (GPX) negatively correlated with calprotectin and PCDAI. Pyc (2 mg/kg) positively influenced the parameters of OS in CD patients after 10 weeks of administration.
Subject(s)
Crohn Disease/metabolism , Flavonoids/pharmacology , Oxidative Stress/drug effects , Adolescent , Amine Oxidase (Copper-Containing)/metabolism , Antioxidants/metabolism , Biomarkers/metabolism , Child , Crohn Disease/diagnosis , Crohn Disease/drug therapy , Female , Flavonoids/administration & dosage , Humans , Inflammation/metabolism , Leukocyte L1 Antigen Complex/metabolism , Male , Mesalamine/administration & dosage , Mesalamine/therapeutic use , Pilot Projects , Plant ExtractsABSTRACT
The work is focused on clarifying the impact of diabetes and natural plant polyphenols contained in Pycnogenol® (PYC) on the activity and synthesis of Cu/Zn-SOD and synthesis of nNOS and eNOS in the cerebellum and cerebral cortex in rats with induced diabetes. Rats included in the study (n=38) were divided into three groups: the controls (C), (n=7), untreated diabetics (D) (n=19) and diabetic rats treated with PYC (DP) (n=12). Diabetes significantly decreased synthesis, as well as the activity of Cu/Zn-SOD in both studied parts of the brain. PYC significantly increased the synthesis of Cu/Zn-SOD but had no effect on its activity. Diabetes also reduced the synthesis of nNOS in cerebral cortex and administered PYC elevated its amount to the level of controls. In the cerebellum, diabetes does not affect the synthesis of nNOS and PYC reduces synthesis of NOS. Diabetes as well as PYC had no influence on the synthesis of eNOS in both, the cerebellum and cerebral cortex. PYC modulated level of Cu/Zn-SOD and nNOS in cerebellum and cerebral cortex of diabetic rats, but in a different way.
